CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, and Vaxart, Inc. (OTCQX: VXRT), a clinical-stage ...

A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine for TB, the world's deadliest infectious disease.

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...

The official opening will be headlined by Dr Nomalungelo Gina, Deputy Minister of Science, Technology and Innovation, who ...

The U.S. government is turning its back on a medical breakthrough that has saved millions of lives, halting $500 million in federal funding to develop new mRNA vaccines against potentially ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

diSArm clinical trial is that our phages injected intravenously can home in to the site of infection, penetrate biofilms, infect, and lyse S. aureus. Many deaths post flu, and most likely also ...

Uncertainty surrounding COVID-19 vaccine recommendations, and potentially other vaccines, may worsen in the coming weeks and months. It is possible parents will continue to see shifting guidance, ...

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...